Entity Central Index Key
Lessee operating lease liability payments due year five and thereafter.
Cover [Abstract]
Document Type
Document Type
Amendment Flag
Amendment Flag
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Trading Symbol
Trading Symbol
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Well-known Seasoned Issuer
Entity Well Known Seasoned Issuer
Entity Voluntary Filers
Entity Voluntary Filers
Entity Current Reporting Status
Entity Current Reporting Status
Entity Filer Category
Entity Filer Category
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Shell Company
Entity Shell Company
Entity File Number
Entity File Number
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address Address Line1
Entity Address, Address Line Two
Entity Address Address Line2
Entity Address, City or Town
Entity Address City Or Town
Entity Address, State or Province
Entity Address State Or Province
Entity Address, Postal Zip Code
Entity Address Postal Zip Code
City Area Code
City Area Code
Local Phone Number
Local Phone Number
Entity Interactive Data Current
Entity Interactive Data Current
Title of 12(b) Security
Security12b Title
Security Exchange Name
Security Exchange Name
Entity Incorporation, State or Country Code
Entity Incorporation State Country Code
Document Annual Report
Document Annual Report
Document Transition Report
Document Transition Report
Entity Public Float
Entity Public Float
Entity Common Stock, Shares Outstanding
Entity Common Stock Shares Outstanding
Statement Of Financial Position [Abstract]
Statement [Table]
Statement [Table]
Class of Stock
Statement Class Of Stock [Axis]
Class of Stock
Class Of Stock [Domain]
Convertible Preferred Stock
Convertible Preferred Stock [Member]
Statement [Line Items]
Statement [Line Items]
Assets
Assets [Abstract]
Current assets:
Assets Current [Abstract]
Cash and cash equivalents
Cash And Cash Equivalents At Carrying Value
Short-term investments
Available For Sale Securities Debt Securities Current
Accounts receivable
Accounts Receivable Net Current
Prepaid expenses and other current assets
Prepaid Expense And Other Assets Current
Total current assets
Assets Current
Property and equipment, net
Property Plant And Equipment Net
Intangible assets, net
Indefinite Lived Intangible Assets Excluding Goodwill
Goodwill
Goodwill
Restricted cash
Restricted Cash Noncurrent
Operating lease right-of-use asset
Operating Lease Right Of Use Asset
Other assets
Other Assets Noncurrent
Total assets
Assets
Liabilities and Stockholders' Equity
Liabilities And Stockholders Equity [Abstract]
Current liabilities:
Liabilities Current [Abstract]
Accounts payable
Accounts Payable Current
Accrued liabilities
Accrued Liabilities Current
Income tax payable
Taxes Payable Current
Deferred revenues, current portion
Contract With Customer Liability Current
Total current liabilities
Liabilities Current
Deferred revenue, net of current portion
Contract With Customer Liability Noncurrent
Operating lease liabilities - long term
Operating Lease Liability Noncurrent
Other long-term liabilities
Other Liabilities Noncurrent
Total liabilities
Liabilities
Commitments and contingencies (Note 11)
Commitments And Contingencies
Stockholders' equity
Stockholders Equity [Abstract]
Convertible preferred stock, $0.00001 par value; 10,000,000 shares authorized at December 31, 2019 and 2018; no shares issued and outstanding at December 31, 2019 and 2018, respectively
Preferred Stock Value
Common stock, $0.00001 par value; 75,000,000 shares authorized at December 31, 2019 and 2018; 45,523,088 and 45,083,209 shares issued and outstanding at December 31, 2019 and 2018, respectively
Common Stock Value
Additional paid-in capital
Additional Paid In Capital
Accumulated other comprehensive income (loss)
Accumulated Other Comprehensive Income Loss Net Of Tax
Accumulated deficit
Retained Earnings Accumulated Deficit
Total stockholders' equity
Stockholders Equity
Total liabilities and stockholders' equity
Liabilities And Stockholders Equity
Convertible Preferred stock, par value
Preferred Stock Par Or Stated Value Per Share
Convertible Preferred stock, shares authorized
Preferred Stock Shares Authorized
Convertible Preferred stock, shares issued
Preferred Stock Shares Issued
Convertible Preferred stock, shares outstanding
Preferred Stock Shares Outstanding
Common stock, par value
Common Stock Par Or Stated Value Per Share
Common stock, shares authorized
Common Stock Shares Authorized
Common stock, shares issued
Common Stock Shares Issued
Common stock, shares outstanding
Common Stock Shares Outstanding
Statement Of Income And Comprehensive Income [Abstract]
Revenues
Revenue From Contract With Customer Excluding Assessed Tax
Type of Revenue [Extensible List]
Type Of Revenue Extensible List
Operating expenses:
Operating Expenses [Abstract]
Research and development
Research And Development Expense
General and administrative
General And Administrative Expense
Total operating expenses
Operating Expenses
Loss from operations
Operating Income Loss
Interest income
Investment Income Interest
Other expense, net
Other Nonoperating Income Expense
Loss before income taxes
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
Provision for (benefit from) income taxes
Income Tax Expense Benefit
Net loss
Net Income Loss
Net loss per share, basic and diluted
Income Loss From Continuing Operations Per Basic And Diluted Share
Shares used to compute net loss per share, basic and diluted
Weighted Average Number Of Share Outstanding Basic And Diluted
Other comprehensive income (loss):
Other Comprehensive Income Loss Tax [Abstract]
Changes in unrealized gain (loss) on short-term investments, net of tax
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
Impact of adoption of new accounting pronouncement
Tax Cuts And Jobs Act Of2017 Reclassification From Aoci To Retained Earnings Tax Effect
Total comprehensive loss
Comprehensive Income Net Of Tax
Number of shares issued during the period as a result of an stock purchase agreement.
Aggregate change in value for stock issued during the period as a result of stock purchase agreement.
Statement Of Stockholders Equity [Abstract]
Equity Components
Statement Equity Components [Axis]
Equity Component
Equity Component [Domain]
Common Stock
Common Stock [Member]
Additional Paid-in Capital
Additional Paid In Capital [Member]
Accumulated Other Comprehensive Income/(Loss)
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit
Retained Earnings [Member]
Adjustments for New Accounting Pronouncements
Adjustments For New Accounting Pronouncements [Axis]
Type of Adoption
Type Of Adoption [Member]
ASU 2014-09
Accounting Standards Update201409 [Member]
ASU 2018-02
Accounting Standards Update201802 [Member]
Beginning balance
Beginning balance, shares
Shares Issued
Impact of adoption of new accounting pronouncements
Cumulative Effect On Retained Earnings Net Of Tax1
Issuance of common stock in follow-on offering, net of issuance costs
Stock Issued During Period Value New Issues
Issuance of common stock in follow-on offering, net of issuance costs, shares
Stock Issued During Period Shares New Issues
Exercise of stock options
Stock Issued During Period Value Stock Options Exercised
Exercise of stock options, shares
Stock Issued During Period Shares Stock Options Exercised
Issuance of common stock under the Employee Stock Purchase Plan
Stock Issued During Period Value Employee Stock Purchase Plan
Issuance of common stock under the Employee Stock Purchase Plan, shares
Stock Issued During Period Shares Employee Stock Purchase Plans
Issuance of common stock to UCSB
Stock Issued During Period Value Issued For Services
Issuance of common stock to UCSB, shares
Stock Issued During Period Shares Issued For Services
Issuance of common stock pursuant to the Amgen Stock Purchase Agreement
Stock Issued During Period Value Stock Purchase Agreement
Issuance of common stock pursuant to the Amgen Stock Purchase Agreement, shares
Stock Issued During Period Shares Stock Purchase Agreement
Stock-based compensation
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Other comprehensive income (loss)
Net loss
Ending balance
Ending balance, shares
Depreciation and amortization excluding amortization of intangible assets.
Increase (decrease) in accrued liabilities, income tax payable and other liabilities noncurrent.
Statement Of Cash Flows [Abstract]
Cash flows from operating activities:
Net Cash Provided By Used In Operating Activities [Abstract]
Net loss
Profit Loss
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]
Amortization of intangible assets
Amortization Of Intangible Assets
Depreciation and amortization
Depreciation And Amortization Excluding Amortization Of Intangible Assets
Amortization of premium (accretion of discount) on investments
Accretion Amortization Of Discounts And Premiums Investments
Stock-based compensation expense
Share Based Compensation
Issuance of common stock in connection with UCSB sublicense fee
Issuance Of Stock And Warrants For Services Or Claims
Non-cash acquisition of in process research and development asset charged to expense
Research And Development In Process
Deferred income taxes
Deferred Income Taxes And Tax Credits
Changes in operating assets and liabilities
Increase Decrease In Operating Capital [Abstract]
Accounts receivable
Increase Decrease In Accounts Receivable
Related party accounts receivable
Increase Decrease In Accounts Receivable Related Parties
Prepaid expenses and other current assets
Increase Decrease In Prepaid Deferred Expense And Other Assets
Other assets
Increase Decrease In Other Operating Assets
Accounts payable
Increase Decrease In Accounts Payable
Accrued liabilities, income tax payable and other long-term liabilities
Increase Decrease In Accrued Liabilities Income Tax Payable And Other Liabilities Noncurrent
Deferred revenue
Increase Decrease In Contract With Customer Liability
Net cash (used in) provided by operating activities
Net Cash Provided By Used In Operating Activities
Cash flows from investing activities:
Net Cash Provided By Used In Investing Activities [Abstract]
Purchases of property and equipment
Payments To Acquire Property Plant And Equipment
Purchases of short-term investments
Payments To Acquire Available For Sale Securities Debt
Maturities of short-term investments
Proceeds From Sale Of Available For Sale Securities Debt
Net cash provided by (used in) investing activities
Net Cash Provided By Used In Investing Activities
Cash flows from financing activities:
Net Cash Provided By Used In Financing Activities [Abstract]
Proceeds from issuance of common stock, net of issuance costs
Proceeds From Issuance Of Common Stock
Proceeds from employee stock purchase plan and exercise of stock options
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
Net cash provided by financing activities
Net Cash Provided By Used In Financing Activities
Net (decrease) increase in cash, cash equivalents and restricted cash
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
Cash, cash equivalents and restricted cash, beginning of year
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
Cash, cash equivalents and restricted cash, end of year
Supplemental disclosures of cash flow information:
Supplemental Cash Flow Information [Abstract]
Cash paid for income taxes
Income Taxes Paid
Supplemental disclosures of noncash investing items:
Noncash Investing And Financing Items [Abstract]
Purchases of property and equipment in accounts payable and accrued liabilities
Capital Expenditures Incurred But Not Yet Paid
Documents Incorporated by Reference
Documents Incorporated By Reference [Text Block]
Disclosure Text Block [Abstract]
Description of the Business
Nature Of Operations
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies
Basis Of Presentation And Significant Accounting Policies [Text Block]
Adopted and recent accounting pronouncements.
Adopted and Recent Accounting Pronouncements
Adopted And Recent Accounting Pronouncements [Text Block]
Earnings Per Share [Abstract]
Net Loss Per Share
Earnings Per Share [Text Block]
Fair Value Disclosures [Abstract]
Fair Value Measurements and Short-Term Investments
Fair Value Disclosures [Text Block]
Property Plant And Equipment [Abstract]
Property and Equipment
Property Plant And Equipment Disclosure [Text Block]
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets
Goodwill And Intangible Assets Disclosure [Text Block]
Accrued Liabilities Current [Abstract]
Accrued Liabilities
Accounts Payable And Accrued Liabilities Disclosure [Text Block]
Research and collaboration agreements.
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Research and Collaboration Agreements
Research And Collaboration Agreements [Text Block]
License agreement.
Research And Development [Abstract]
License Agreement
License Agreement Disclosure [Text Block]
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies
Commitments And Contingencies Disclosure [Text Block]
Leases [Abstract]
Leases
Lessee Operating Leases [Text Block]
Equity [Abstract]
Common Stock
Stockholders Equity Note Disclosure [Text Block]
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation
Disclosure Of Compensation Related Costs Share Based Payments [Text Block]
Income Tax Disclosure [Abstract]
Income Taxes
Income Tax Disclosure [Text Block]
Compensation And Retirement Disclosure [Abstract]
Defined Contribution Plan
Pension And Other Postretirement Benefits Disclosure [Text Block]
Quarterly Financial Information Disclosure [Abstract]
Supplementary Data – Quarterly Financial Data (Unaudited)
Quarterly Financial Information [Text Block]
Subsequent Events [Abstract]
Subsequent Events
Subsequent Events [Text Block]
Basis of Presentation
Basis Of Accounting Policy Policy [Text Block]
Use of Estimates
Use Of Estimates
Concentration of Credit Risk and Other Risks and Uncertainties
Concentration Risk Credit Risk
Segments
Segment Reporting Policy Policy [Text Block]
Cash and Cash Equivalents
Cash And Cash Equivalents Policy [Text Block]
Restricted Cash
Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy
Short-term Investments
Marketable Securities Policy
Property and Equipment, net
Property Plant And Equipment Policy [Text Block]
Goodwill and Intangible Assets
Goodwill And Intangible Assets Policy [Text Block]
Impairment of Long-Lived Assets
Impairment Or Disposal Of Long Lived Assets Policy [Text Block]
Revenue Recognition
Revenue Recognition Policy [Text Block]
Comprehensive Loss
Comprehensive Income Policy Policy [Text Block]
Contract Balances
Revenue From Contract With Customer Policy [Text Block]
Stock-Based Compensation
Share Based Compensation Option And Incentive Plans Policy
Income Taxes
Income Tax Policy [Text Block]
Research and Development Expenses
Research And Development Expense Policy
Leases
Lessee Leases Policy [Text Block]
Adopted Accounting Pronouncements and Recent Accounting Pronouncements
New Accounting Pronouncements Policy Policy [Text Block]
Schedule of Customers and Collaboration Partners who Represent 10% or More of Total Revenue During Each Period Presented or Net Accounts Receivable Balance
Schedules Of Concentration Of Risk By Risk Factor [Text Block]
Schedule of cash, cash equivalents, and restricted cash.
Schedule of Cash, Cash Equivalents, and Restricted Cash
Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]
Tabular disclosure of property plant and equipment estimated useful lives.
Schedule of Useful Lives of Property and Equipment
Property Plant And Equipment Estimated Useful Lives Table [Text Block]
Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]
Schedule of Short-Term Investments Subject to Fair Value Measurements on a Recurring Basis
Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]
Summary of Property and Equipment, Net
Property Plant And Equipment [Text Block]
Schedule of Goodwill and Intangible Assets
Schedule Of Intangible Assets And Goodwill Table [Text Block]
Schedule of Accrued Liabilities
Schedule Of Accrued Liabilities Table [Text Block]
Schedule of Revenue by Collaboration Partner
Disaggregation Of Revenue Table [Text Block]
Summary of Contract Liabilities
Contract With Customer Asset And Liability Table [Text Block]
Supplemental information related to leases.
Summary of Supplemental Information Related to Leases
Supplemental Information Related To Leases Table [Text Block]
Schedule Reserved Shares of Common Stock Issuance on Converted Basis
Schedule Of Stock By Class [Text Block]
Schedule of Activity Under Company's Stock Option Plans
Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]
Total Stock-based Compensation Recognized
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]
Schedule of Estimated Fair Value of Employee Stock Options and ESPP Using Black-Scholes Valuation Model
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]
Schedule of Components of Provision for (Benefit from) Income Taxes
Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]
Schedule of Effective Tax Rate Reconciliation
Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]
Schedule of Deferred Income Tax Liabilities
Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]
Schedule of Reconciliation of Unrecognized Tax Benefits
Summary Of Income Tax Contingencies [Text Block]
Unaudited Financial Information
Schedule Of Quarterly Financial Information Table [Text Block]
Concentration Risk [Table]
Concentration Risk [Table]
Customer
Major Customers [Axis]
Customer
Name Of Major Customer [Domain]
Major customer [Member].
Major Customer
Major Customer [Member]
Counterparty Name
Counterparty Name [Axis]
Counterparty Name
Repurchase Agreement Counterparty Name [Domain]
AbbVie Ireland Unlimited Company.
AbbVie Ireland Unlimited Company
Abb Vie Ireland Unlimited Company [Member]
Bristol-Myers Squibb Company.
Bristol Myers Squibb Company
Bristol Myers Squibb Company [Member]
ImmunoGen, Inc.
Immuno Gen Inc
Immuno Gen Inc [Member]
Concentration Risk [Line Items]
Concentration Risk [Line Items]
Revenue
Accounts Receivable, net
Number of business activities.
Summary of significant accounting policies.
Summary of significant accounting policies.
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Table]
Initial Application Period Cumulative Effect Transition
Initial Application Period Cumulative Effect Transition [Axis]
Initial Application Period Cumulative Effect Transition
Initial Application Period Cumulative Effect Transition [Domain]
Adjustments
Difference Between Revenue Guidance In Effect Before And After Topic606 [Member]
ASC 606
Finite-Lived Intangible Assets by Major Class
Finite Lived Intangible Assets By Major Class [Axis]
Finite-Lived Intangible Assets, Major Class Name
Finite Lived Intangible Assets Major Class Name [Domain]
Probody technology.
Probody technology
Probody Technology [Member]
Summary Of Significant Accounting Policies [Line Items]
Summary Of Significant Accounting Policies [Line Items]
Number of business activities
Number Of Business Activities
Number of operating segments
Number Of Operating Segments
Cash And Cash Equivalents [Abstract]
Cash, cash equivalents, and restricted cash
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
Schedule Of Property Plant And Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Property, Plant and Equipment, Type
Property Plant And Equipment By Type [Axis]
Property, Plant and Equipment, Type
Property Plant And Equipment Type [Domain]
Machinery and equipment
Machinery And Equipment [Member]
Computer equipment and software.
Computer equipment and software
Computer Equipment And Software [Member]
Furniture and fixtures
Furniture And Fixtures [Member]
Leasehold improvements
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment [Line Items]
Estimated useful life of property and equipment
Property Plant And Equipment Useful Life
Estimated useful life of leasehold improvements, description
Property Plant And Equipment Estimated Useful Lives
Impairment of goodwill
Goodwill Impairment Loss
Impairment of intangible assets
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
Impairment of long-lived assets
Impairment Of Long Lived Assets Held For Use
Increase in accumulated deficit balance
Acquired, technology know-how
Finitelived Intangible Assets Acquired1
Research and development expense
ASC 842
Accounting Standards Update201602 [Member]
Right-of-use asset
Lease liability
Operating Lease Liability
Increase in other comprehensive income
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Derivative Instrument
Derivative Instrument Risk [Axis]
Derivative Contract
Derivative Contract Type [Domain]
Options to purchase common stock
Stock Option [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value Hierarchy and NAV
Fair Value By Fair Value Hierarchy Level [Axis]
Fair Value Hierarchy and NAV
Fair Value Measurements Fair Value Hierarchy [Domain]
Level I
Fair Value Inputs Level1 [Member]
Asset Class
Fair Value By Asset Class [Axis]
Asset Class
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]
Money market funds
Money Market Funds [Member]
Money market funds included in restricted cash.
Restricted cash (money market funds)
Money Market Funds Included In Restricted Cash [Member]
U. S. Government bonds
U S Treasury And Government [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Amortized Cost
Available For Sale Securities Amortized Cost
Gross Unrealized Holding Gains
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
Gross Unrealized Holding Losses
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
Aggregate Fair Value
Available For Sale Securities
Amortized Cost
Available For Sale Debt Securities Amortized Cost Basis
Gross Unrealized Holding Gains
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
Gross Unrealized Holding Losses
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
Aggregate Fair Value
Available For Sale Securities Debt Securities
Contractual maturities of longer than one year
Available For Sale Securities Debt Maturities Within One Year Fair Value
Computer equipment and software gross.
Machinery and equipment
Machinery And Equipment Gross
Computer equipment and software
Computer Equipment And Software Gross
Furniture and fixtures
Furniture And Fixtures Gross
Leasehold improvements
Leasehold Improvements Gross
Construction in progress
Construction In Progress Gross
Total property and equipment
Property Plant And Equipment Gross
Less: accumulated depreciation and amortization
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Property and equipment, net
Depreciation and amortization
Depreciation
Schedule Of Finite Lived Intangible Assets [Table]
Schedule Of Finite Lived Intangible Assets [Table]
IPR&D [Member]
In Process Research And Development [Member]
Finite Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets [Line Items]
Average estimated lives of patents
Acquired Finite Lived Intangible Assets Weighted Average Useful Life
Amortization expense of intangible assets
Goodwill.
Goodwill and intangible assets.
Schedule of goodwill and intangible assets.
Schedule Of Goodwill And Intangible Assets [Table]
Schedule Of Goodwill And Intangible Assets [Table]
In-Process Research and Development
Goodwill And Intangible Assets [Line Items]
Goodwill And Intangible Assets [Line Items]
Goodwill
Goodwill [Abstract]
Intangible assets
Finite Lived Intangible Assets Net [Abstract]
Intangible assets, gross
Finite Lived Intangible Assets Gross
Less accumulated amortization
Finite Lived Intangible Assets Accumulated Amortization
Intangible assets, net
Finite Lived Intangible Assets Net
Accrued research and clinical current.
Research and clinical expenses
Accrued Research And Clinical Current
Payroll and related expenses
Employee Related Liabilities Current
Legal and professional expenses
Accrued Professional Fees Current
Operating lease liabilities - short term
Operating Lease Liability Current
Other accrued expenses
Other Accrued Liabilities Current
Total
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
AbbVie
Amgen Inc.
Amgen
Amgen Inc [Member]
ImmunoGen
Pfizer Inc.
Pfizer
Pfizer Inc [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue
Revenues
Number of collaboration agreements.
Percentage of net Income or net losses related to development costs.
Collaborative Arrangement and Arrangement Other than Collaborative
Type Of Arrangement [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Arrangements And Nonarrangement Transactions [Member]
Collaborative Arrangement
Collaborative Arrangement [Member]
Statistical Measurement
Range [Axis]
Statistical Measurement
Range [Member]
Maximum
Maximum [Member]
Minimum
Minimum [Member]
Geographical
Statement Geographical [Axis]
Geographical
Segment Geographical [Domain]
U.S
UNITED STATES
CD 71 agreement.
CD71 Agreement
C D71 Agreement [Member]
Seattle genetics agreement.
Seattle Genetics Agreement
Seattle Genetics Agreement [Member]
Discovery agreement.
Discovery Agreement
Discovery Agreement [Member]
Contingent Consideration by Type
Contingent Consideration By Type [Axis]
Contingent Consideration Type
Contingent Consideration Type [Domain]
Development regulatory and commercial milestone payments.
Development, Regulatory and Commercial Milestone Payments
Development Regulatory And Commercial Milestone Payments [Member]
Product and Service
Product Or Service [Axis]
Product and Service
Products And Services [Domain]
Second target.
Second Target
Second Target [Member]
License agreement.
License Agreement
License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others, Type
Research And Development Arrangement Contract To Perform For Others By Type [Axis]
Research and Development Arrangement, Contract to Perform for Others, Type
Research And Development Arrangement Contract To Perform For Others Type [Domain]
Regents of the university of California.
UC Regents
Regents Of The University Of California [Member]
University of California, Santa Barbara.
UCSB
University Of California Santa Barbara [Member]
Number of collaboration agreements
Number Of Collaboration Agreements
Percentage of net profits or net losses related to development costs
Percentage Of Net Income Or Net Losses Related To Development Costs
Contingent payments receivable upon achieving development, regulatory and commercial milestones.
Contingent payments receivable profit split on sales.
Milestone payments received from revenue recognized during period.
Payments of sublicense fees.
Upfront payment received
Proceeds From Collaborators
Contingent payments receivable upon achieving development, regulatory and commercial milestones
Contingent Payments Receivable Upon Achieving Development Regulatory And Commercial Milestones
Profit split on U.S. sales and royalties on ex U.S. sales
Contingent Payments Receivable Profit Split On Sales
Milestone payment received
Milestone Payments Received From Revenue Recognized During Period
Sublicense fees paid
Payments Of Sublicense Fees
Number of targets.
Number of targets selected.
Number of targets
Number Of Targets
Number of targets selected
Number Of Targets Selected
Future contingent milestone payment receivable.
Milestone payment received.
Milestone payments received
Milestone Payment Received
Contingent milestone payments receivable
Contingent Milestone Payments Receivable
Aggregate collaboration transaction amount.
Estimated sublicense fees.
Number of accounting units.
Milestone payments receivable.
Total transaction price
Aggregate Collaboration Transaction Amount
Estimated sublicense fees
Estimated Sublicense Fees
Number of accounting units
Number Of Accounting Units
Milestone payment received
Milestone Payments Receivable
Revenue adjustment of milestone payment recognized.
Revenue adjustment of milestone payment recognized
Revenue Adjustment Of Milestone Payment Recognized
License payment percentage equivalence to upfront and milestone proceeds.
License payment percentage
License Payment Percentage Equivalence To Upfront And Milestone Proceeds
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]
Revenue recognition upon performance obligation, service period
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
Estimated research service period.
Revenue recognition upon performance obligation
Revenue Remaining Performance Obligation
Estimated research service period
Estimated Research Service Period
Revenue recognized from collaborative arrangement
Deferred revenue
Contract With Customer Liability
Amount due from agreement
Contract With Customer Asset Net
Common stock shares issuable under agreement.
Period used to calculate weighted average price per share.
Lock-up period for share transaction under collaboration and license agreement.
Estimated premium on issuance of shares.
Collaboration and license agreement.
Collaboration and License Agreement
Collaboration And License Agreement [Member]
Amgen Inc
EGFR Products.
EGFR Products
E G F R Products [Member]
Sublicense agreement.
Sublicense Agreement
Sublicense Agreement [Member]
Amgen other products.
Amgen Other Products
Amgen Other Products [Member]
Common stock, shares issuable under agreement
Common Stock Shares Issuable Under Agreement
Common stock, shares issuable under agreement, price per share
Share Price
Common stock, value of shares issued in connection with agreement
Period used to calculate weighted average price per share
Period Used To Calculate Weighted Average Price Per Share
Lock-up period for share disposal
Lock Up Period For Share Transaction Under Collaboration And License Agreement
Estimated premium on the stock sold
Estimated Premium On Issuance Of Shares
Profit share upon exercise of co-development option.
Percentage share of profit and losses
Profit Share Upon Exercise Of Co Development Option
Number of additional collaboration target.
Number of additional collaboration target
Number Of Additional Collaboration Target
Contingent payments payable upon achieving development regulatory and commercial milestones.
Contingent payments payable
Contingent Payments Payable Upon Achieving Development Regulatory And Commercial Milestones
Premium on issuance of shares allocated to common stock.
Estimated fair value of products.
Portion of transaction price allocated to premium on sale of common stock
Premium On Issuance Of Shares Allocated To Common Stock
Estimated fair value of products
Estimated Fair Value Of Products
Estimated full time employee hours and research service period.
Estimated FTE hours to completion and research service period
Estimated Full Time Employee Hours And Research Service Period
Number of oncology target.
Number of collaboration target.
Collaboration target research term.
Period of nomination of additional target.
Extension of research term for each collaboration target.
Increments of extended collaboration target research times.
Achieving additional targets.
Each Of Two Additional Targets
Achieving Additional Targets [Member]
Achievement of development milestones for each research target program.
Achievement Of Development Milestones For Each Research Target Program
Achievement Of Development Milestones For Each Research Target Program [Member]
Achievement of development milestones if four research targets selected by counterparty.
Achievement Of Development Milestones If Four Research Targets Selected By Counterparty
Achievement Of Development Milestones If Four Research Targets Selected By Counterparty [Member]
Upon first commercial sale.
Achieving First Commercial Sale In Various Territories
Achieving First Commercial Sale In Various Territories [Member]
Achieving first commercial sale if four research targets selected by counterparty.
Achieving First Commercial Sale If Four Research Targets Selected By Counterparty
Achieving First Commercial Sale If Four Research Targets Selected By Counterparty [Member]
Achieving sales milestones for each research target program.
Achieving Sales Milestones For Each Research Target Program
Achieving Sales Milestones For Each Research Target Program [Member]
Achieving sales milestones if four research targets selected by counterparty.
Achieving Sales Milestones If Four Research Targets Selected By Counterparty
Achieving Sales Milestones If Four Research Targets Selected By Counterparty [Member]
Pre clinical candidate.
Pre Clinical Candidate
Pre Clinical Candidate [Member]
Drug application for CTLA-4.
New Drug Application for CTLA-4
Drug Application For C T L A4 [Member]
Achievement of development milestones if eight research targets selected by counterparty.
Achievement of Development Milestones if Eight Research Targets Selected by Counterparty
Achievement Of Development Milestones If Eight Research Targets Selected By Counterparty [Member]
Achieving eight targets selected for first product modality.
Achieving Eight Targets Selected for the First Product Modality
Achieving Eight Targets Selected For First Product Modality [Member]
Achieving sales milestones if eight research targets selected for first product modality.
Achieving Sales Milestones if Eight Research Targets Selected for First Product Modality
Achieving Sales Milestones If Eight Research Targets Selected For First Product Modality [Member]
Achieving development milestone payments.
Achieving Development Milestone Payments
Achieving Development Milestone Payments [Member]
Achieving development milestone payment if eight research targets are selected for second product modality.
Achieving Development Milestone Payment if Eight Targets are Selected for Second Product Modality
Achieving Development Milestone Payment If Eight Research Targets Are Selected For Second Product Modality [Member]
Milestone payments for the first commercial sale in various territories for up to three indications.
Achieving Milestone Payments for First Commercial Sale in Various Territories for Up to Three Indication
Achieving Milestone Payments For First Commercial Sale In Various Territories For Up To Three Indications [Member]
Achieving milestone payment if eight research target are selected for second product modality.
Achieving Development Milestone Payment if Eight Targets are Selected for Second Product Modality
Achieving Milestone Payment If Eight Research Target Are Selected For Second Product Modality [Member]
Achieving sales milestone payments per target.
Achieving Sales Milestone Payments Per Target
Achieving Sales Milestone Payments Per Target [Member]
Achieving sales milestone payment if eight research target are selected for second product modality.
Achieving Sales Milestone Payment if Eight Research Target are selected for Second Product Modality
Achieving Sales Milestone Payment If Eight Research Target Are Selected For Second Product Modality [Member]
Third and fourth targets.
Third And Fourth Immuno-Oncology Targets
Third And Fourth Targets [Member]
Number of oncology target
Number Of Oncology Target
Number of collaboration target
Number Of Collaboration Target
Collaboration target research term
Collaboration Target Research Term
Research terms
Research And Development Arrangement Contract To Perform For Others Description And Terms
Period of nomination of additional target from effective date
Period Of Nomination Of Additional Target
Extension of research term for each collaboration target
Extension Of Research Term For Each Collaboration Target
Times of increments for extended collaboration target research time
Increments Of Extended Collaboration Target Research Times
Number of research targets selected.
Number of sales indicators for each research target program.
Number of research targets selected
Number Of Research Targets Selected
Number of sales indicators
Number Of Sales Indicators For Each Research Target Program
Number of non-oncology target.
Number of non-oncology target
Number Of Non Oncology Target
Research and development service fees.
Estimated research service termination date.
Upfront payment received
Research And Development Service Fees
Estimated research service termination date
Estimated Research Service Termination Date
Cash payment to execute the agreement.
CX-2009 License
License Agreement Terms [Member]
Transaction Type
Transaction Type [Axis]
Transaction
Transaction [Domain]
License receivables.
Licenses Received
License Receivables [Member]
Research services, joint research committee participation and technology improvements.
Research Services, Joint Research Committee Participation and Technology Improvements
Research Services Joint Research Committee Participation And Technology Improvements [Member]
Upfront cash payment
Cash Payment To Execute Agreement
Milestones payments made during period.
Contingent payments receivable upon achieving development and regulatory milestones.
Expected receivable from sales mile stone payments.
Contingent payments payable upon achieving development and regulatory milestones.
Contingent payments payable upon achieving sales milestones.
Milestone payment payable.
Contingent payments receivable upon achieving development and regulatory milestones
Contingent Payments Receivable Upon Achieving Development And Regulatory Milestones
Contingent payments receivable upon achieving sales milestones
Contingent Payments Receivable Upon Achieving Sales Milestones
Contingent payments payable upon achieving development and regulatory milestones
Contingent Payments Payable Upon Achieving Development And Regulatory Milestones
Contingent payments payable upon achieving sales milestones
Contingent Payments Payable Upon Achieving Sales Milestones
Milestones payments made during period
Milestones Payments Made During Period
Milestone payments payable
Milestone Payment Payable
Estimated total fair value consideration recorded as deferred revenue
Estimated fair value of assets and services.
Estimated fair value of assets and services
Estimated Fair Value Of Assets And Services
Option expiration date.
MD Anderson.
MD Anderson
M D Anderson [Member]
Option expiration date
Options Expiration Date
Number of nominated research targets.
Number of additional research targets.
Contract with customer liability additions.
Pfizer Inc
Number of research targets
Number Of Nominated Research Targets
Nominated number of additional research targets
Number Of Additional Research Targets With Nomination Option
Additional target as deferred revenue
Contract With Customer Liability Additions
Amortization period of deferred revenue.
Adjusted amortization period of deferred revenue
Amortization Period Of Deferred Revenue
Revenue From Contract With Customer [Abstract]
Balance at 12/31/2018
Additions
Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
Deductions
Contract With Customer Liability Revenue Recognized
Balance at 12/31/2019
First target.
First Target
First Target [Member]
Additions to deferred revenue
Deductions to deferred revenue recognized during the period
Contract with customer liability maturity month and year.
Deferred revenue recognition maturity month and year
Contract With Customer Liability Maturity Month And Year
Royalty obligations future minimum payments due.
Period of time to terminate license after notice date.
Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]
Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]
Income Statement Location
Income Statement Location [Axis]
Income Statement Location
Income Statement Location [Domain]
Sublicense and maintenance fees.
Sublicense and Maintenance Fees
Sublicense And Maintenance Fees [Member]
AbbVie .
AbbVie
Abb Vie [Member]
License Agreement [Line Items]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Annual minimum royalty obligations
Royalty Obligations Future Minimum Payments Due
License termination period
License Termination Period
Payment of upfront fees.
Annual license maintenance fees
License payment term.
Percentage of remaining maintenance fees outstanding.
Fair value of common stock issued.
Fair value of common stock price per share
Shares Issued Price Per Share
Payment of upfront fees
Payment Of Upfront Fees
Annual license maintenance fees
Annual License Maintenance Fees
License payment term
License Payment Term
Percentage of remaining maintenance fees outstanding
Percentage Of Remaining Maintenance Fees Outstanding
Fair value of common stock issued
Fair Value Of Common Stock Issued
Additional sublicense fees.
Milestone payment receivable.
Additional sublicense fees
Additional Sublicense Fees
Milestone payment receivable
Milestone Payment Receivable
Sublicense fees.
Sublicense fees
Sublicense Fees
Accrued liabilities
Upfront license payment.
Upfront license payment
Upfront License Payment
Schedule Of Operating Leased Assets [Table]
Schedule Of Operating Leased Assets [Table]
New Lease Agreement
Lease Agreements [Member]
Lease Arrangement, Type
Lease Arrangement Type [Axis]
Lease Arrangement, Type
Lease Arrangement Type [Domain]
First year of lease term.
First year of lease term
First Year Of Lease Term [Member]
Second twelve months of lease term.
Second twelve months of lease term
Second Twelve Months Of Lease Term [Member]
Tenth year of lease term.
Tenth year of lease term
Tenth Year Of Lease Term [Member]
Credit Facility
Credit Facility [Axis]
Credit Facility
Credit Facility [Domain]
Letter of Credit
Letter Of Credit [Member]
Operating Leased Assets [Line Items]
Operating Leased Assets [Line Items]
Area of rentable office and laboratory space
Area Of Land
Lease term description
Lessee Operating Lease Description
Initial lease term
Lessee Operating Lease Term Of Contract
Extended lease term
Lessee Operating Lease Renewal Term
Operating leases rent expense annual base rent.
Maximum improvement allowance.
Improvement allowance from recoverable rent.
Annual lease rent
Operating Leases Rent Expense Annual Base Rent
Maximum one-time improvement allowance
Maximum Improvement Allowance
Improvement allowance from recoverable rent
Improvement Allowance From Recoverable Rent
Letter of credit outstanding, amount
Letters Of Credit Outstanding Amount
Rent expense
Operating Lease Expense
Cash paid for amounts included in measurement of lease liabilities.
Supplemental balance sheet information related to leases.
Weighted average remaining lease term.
Weighted average discount rate.
Cash paid for amounts included in the measurement of lease liabilities
Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]
Operating cash flows from operating leases
Operating Lease Payments
Supplemental balance sheet information related to leases:
Supplemental Balance Sheet Information Related To Leases [Abstract]
Operating lease right-of-use assets
Current operating lease liabilities
Non-current operating lease liabilities
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]
Operating Lease Liability Current Statement Of Financial Position Extensible List
Total operating lease liabilities
Weighted-average remaining lease term (in years)
Weighted Average Remaining Lease Term [Abstract]
Operating lease
Operating Lease Weighted Average Remaining Lease Term1
Weighted-average discount rate
Weighted Average Discount Rate [Abstract]
Operating lease
Operating Lease Weighted Average Discount Rate Percent
Maturity of operating lease liabilities
Operating Lease Liabilities Payments Due [Abstract]
2020
Lessee Operating Lease Liability Payments Due Next Twelve Months
2021
Lessee Operating Lease Liability Payments Due Year Two
2022
Lessee Operating Lease Liability Payments Due Year Three
2023
Lessee Operating Lease Liability Payments Due Year Four
2024 and beyond
Lessee Operating Lease Liability Payments Due Year Five And Thereafter
Total lease payments
Lessee Operating Lease Liability Payments Due
Less imputed interest
Lessee Operating Lease Liability Undiscounted Excess Amount
Present value of lease liabilities
Schedule Of Stock By Class [Table]
Schedule Of Stock By Class [Table]
Sale of Stock
Subsidiary Sale Of Stock [Axis]
Sale of Stock
Sale Of Stock Name Of Transaction [Domain]
Underwritten public offering.
Underwritten Public Offering
Underwritten Public Offering [Member]
Underwriters
Over Allotment Option [Member]
Class Of Stock [Line Items]
Class Of Stock [Line Items]
Preferred stock, shares authorized
Preferred stock, par value
Dividends on common stock
Dividends Common Stock
Common stock price, per share
Net proceeds from sale of common stock
Underwriting discounts and commissions and offering expenses
Payments Of Stock Issuance Costs
Stock options issued and outstanding.
Share-based compensation arrangement by share-based payment award, number of shares available for future issuance under employee stock purchase plan.
Options issued and outstanding
Stock Options Issued And Outstanding
Shares available for future stock option grants
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
Shares available for future employee stock purchase plan
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Future Issuance Under Employee Stock Purchase Plan
Total
Common Stock Capital Shares Reserved For Future Issuance
Share based compensation arrangement by share based payment award voting rights of common stock holding percentage.
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Plan Name
Plan Name [Axis]
Plan Name
Plan Name [Domain]
Two thousand fifteen stock incentive plan.
2015 Plan
Two Thousand Fifteen Stock Incentive Plan [Member]
Two Thousand Nineteen Stock Incentive Plan Member.
2019 Plan
Two Thousand Nineteen Stock Incentive Plan [Member]
Vesting
Vesting [Axis]
Vesting
Vesting [Domain]
Share Based Compensation Award Tranche One
Share Based Compensation Award Tranche One [Member]
Vesting per Month After First Anniversary
Share Based Compensation Award Tranche Two [Member]
Award Type
Award Type [Axis]
Award Type
Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]
Employee Stock Option
Employee Stock Option [Member]
Early exercise of employee options.
Early Exercise of Employee Options
Early Exercise Of Employee Options [Member]
Employee stock purchase plan.
Employee Stock Purchase Plan
Employee Stock Purchase Plan [Member]
Non-Employees Member.
Non-employees
Non Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance
Increase in number of shares available for issuance, as proportion of issued and outstanding shares of common stock, percentage
Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
Stock option expiration period
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
Employees holding voting rights of all classes of stock, percentage
Share Based Compensation Arrangement By Share Based Payment Award Voting Rights Of Common Stock Holding Percentage
Estimated fair value of the shares on the date of grant
Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
Options granted generally vest period
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
Options granted generally vest percent
Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
Share based compensation arrangement by share based payment award number of shares available for grant authorized.
Share based compensation arrangement by share based payment award number of shares available for grant grants in period.
Share based compensation arrangement by share based payment award number of shares available for grant exercises in period.
Share based compensation arrangement by share based payment award number of shares available for grant forfeitures in period.
Share based compensation arrangement by share based payment award, number of shares available for grant.
Options Available for Grant
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant [Abstract]
Balances, beginning of the period
Options authorized
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Authorized
Options granted
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period
Options exercised
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercises In Period
Options forfeited
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
Balances, end of the period
Share based compensation arrangement by share based payment award options authorized.
Number of Options
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Balances, beginning of the period
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
Options authorized
Share Based Compensation Arrangement By Share Based Payment Award Options Authorized
Options granted
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Options exercised
Options forfeited
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
Balances, end of the period
Options Exercisable, end of the period
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
Options vested and expected to vest, end of the period
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
Share based compensation arrangements by share based payment award options authorized weighted average exercise price.
Options Outstanding, Weighted-Average Exercise Price Per Share
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward
Balances, beginning of the period
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Options granted
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Options exercised
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
Options forfeited
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
Balances, end of the period
Options authorized
Share Based Compensation Arrangements By Share Based Payment Award Options Authorized Weighted Average Exercise Price
Options Exercisable, end of the period
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
Options vested and expected to vest, end of the period
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
Options Outstanding, Weighted- Average Remaining Contractual Life (years)
Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]
Balances, end of the period
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
Options Exercisable, end of the period
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
Options vested and expected to vest, end of the period
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
Share based compensation arrangement by share based payment award options aggregate intrinsic value.
Aggregate Intrinsic Value
Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]
Balances, end of the period
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
Options Exercisable—December 31, 2019
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
Options vested and expected to vest—December 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
Aggregate intrinsic value of stock options exercised
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
Weighted average grant date fair value, options granted
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
Unrecognized compensation expense, options granted to employees
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
Unrecognized stock-based compensation cost, period for recognition
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
Plan maximum percentage of eligible compensation to purchase shares
Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
Number of shares issued during period
Stock-based compensation expense
Allocated Share Based Compensation Expense
Unrecognized stock-based compensation cost
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
Research and development
Research And Development Expense [Member]
General and administrative
General And Administrative Expense [Member]
Stock-based compensation expense:
Share Based Compensation [Abstract]
Stock-based compensation expense
Expected volatility, minimum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
Expected volatility, maximum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
Risk-free interest rate, minimum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
Risk-free interest rate, maximum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
Dividend yield
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
Expected term (in years)
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
Current:
Current Federal State And Local Tax Expense Benefit [Abstract]
Federal
Current Federal Tax Expense Benefit
State
Current State And Local Tax Expense Benefit
Total current
Current Income Tax Expense Benefit
Deferred:
Deferred Income Tax Expense Benefit Continuing Operations [Abstract]
Federal
Deferred Federal Income Tax Expense Benefit
State
Deferred State And Local Income Tax Expense Benefit
Total deferred
Deferred Income Tax Expense Benefit
Provision for (benefit from) income taxes
Effective income tax rate reconciliation operating loss carry forward limitation.
Effective income tax rate reconciliation return to provision adjustments.
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]
U.S. federal taxes at statutory rate
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
State tax, net of federal benefit
Effective Income Tax Rate Reconciliation State And Local Income Taxes
Stock compensation
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
Tax attributes subject to 382 limitation
Effective Income Tax Rate Reconciliation Operating Loss Carry Forward Limitation
Tax credits
Effective Income Tax Rate Reconciliation Tax Credits
Change in valuation allowance
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
Change in deferreds due to rate change
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
Return to provision adjustment
Effective Income Tax Rate Reconciliation Return To Provision Adjustments
Other
Effective Income Tax Rate Reconciliation Other Adjustments
Total
Effective Income Tax Rate Continuing Operations
Deferred tax assets lease liability.
Deferred tax liabilities right of use assets.
Components Of Deferred Tax Assets And Liabilities [Abstract]
Net operating loss carryforwards
Deferred Tax Assets Operating Loss Carryforwards
Research and development credits
Deferred Tax Assets Tax Credit Carryforwards Research
Lease liability
Deferred Tax Assets Lease Liability
Intangible assets
Deferred Tax Assets Goodwill And Intangible Assets
Deferred revenue
Deferred Tax Assets Deferred Income
Accruals and deferred rent
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
Stock-based compensation
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
Other
Deferred Tax Assets Other
Total gross deferred income tax assets
Deferred Tax Assets Gross
Less: valuation allowance
Deferred Tax Assets Valuation Allowance
Deferred tax assets, net of valuation allowance
Deferred Tax Assets Net
Fixed assets
Deferred Tax Liabilities Property Plant And Equipment
Right-of-use assets
Deferred Tax Liabilities Right Of Use Assets
Intangible assets
Deferred Tax Liabilities Goodwill And Intangible Assets
Prepaid expenses
Deferred Tax Liabilities Prepaid Expenses
Other
Deferred Tax Liabilities Other
Deferred tax liabilities
Deferred Income Tax Liabilities
Net deferred income tax liabilities
Deferred Tax Liabilities
Income Tax Contingency [Table]
Income Tax Contingency [Table]
Income Tax Authority
Income Tax Authority [Axis]
Income Tax Authority
Income Tax Authority [Domain]
Federal
Domestic Country [Member]
State
State And Local Jurisdiction [Member]
Tax Credit Carryforward
Tax Credit Carryforward [Axis]
Tax Credit Carryforward, Name
Tax Credit Carryforward Name [Domain]
Research and Development Tax Credits
Research [Member]
Minimum
Income Tax Contingency [Line Items]
Income Tax Contingency [Line Items]
Deferred tax asset, net change in total valuation allowance increase during period
Valuation Allowance Deferred Tax Asset Change In Amount
Operating loss carryforwards expiration year.
Operating loss carryforwards amount to expire if not used.
Operating loss carryforwards amount not subject to expiration.
Net operating loss carryforwards
Operating Loss Carryforwards
Operating loss carryforwards expiration year
Operating Loss Carryforwards Expiration Year
Operating loss carryforwards to expire if not utilized
Operating Loss Carryforwards Amount To Expire If Not Used
Operating loss carryforwards not subject to expiration
Operating Loss Carryforwards Amount Not Subject To Expiration
Tax credit carryforward expiration year.
Reduction to tax credit carryforwards
Tax Credit Carryforward Amount
Tax credit carryforward, expiration
Tax Credit Carryforward Expiration Year
Percentage of change in ownership.
Percentage of change in ownership
Percentage Of Change In Ownership
Unrecognized tax benefits
Unrecognized Tax Benefits
Unrecognized tax benefits would affect company's effective tax rate
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
Amount of increase decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward
Balance at the beginning of the year
Additions based on tax positions related to current year
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
Adjustment based on tax positions related to prior years
Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
Balance at end of the year
Interest and penalties accrued
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
Open tax year
Open Tax Year
Company contributions to defined contribution plan
Defined Contribution Plan Employer Discretionary Contribution Amount
Net income (loss)
Net loss per share attributable to common stockholders, basic and diluted
Subsequent Event [Table]
Subsequent Event [Table]
Subsequent Event Type
Subsequent Event Type [Axis]
Subsequent Event Type
Subsequent Event Type [Domain]
Subsequent Event
Subsequent Event [Member]
Subsequent Event [Line Items]
Subsequent Event [Line Items]